atorvastatin has been researched along with digoxin in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Boyd, RA; Randinitis, EJ; Reyner, EL; Stern, RH; Stewart, BH; Whitfield, L; Wu, X; Zegarac, EA | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Bizot, MN; Camenisch, G; Dieterich, HA; Dole, WP; Howard, D; Reynolds, C; Schuetz, H; Vaidyanathan, S; Yeh, CM | 1 |
| Chedgy, F; Howlett, DC; Inglis, C | 1 |
| Becka, M; Kubitza, D; Mueck, W; Roth, A | 1 |
| Benet, LZ; Estudante, M; Maya, M; Morais, JG; Soveral, G | 1 |
| Ekblom, M; Lennernäs, H; Malm-Erjefält, M; Vouis, J; Zdravkovic, M | 1 |
| Fromm, MF; Glaeser, H; Hoier, E; Knop, J; König, J; Misaka, S; Müller, F; Singer, K | 1 |
| Akhtar, S; Desai, A; Goldwater, R; Han, D; Howieson, C; Kowalski, D; Lademacher, C; Lasseter, KC; Rammelsberg, D; Townsend, R; Yamazaki, T | 1 |
| Anderson, TW; Derving Karsbøl, J; Golor, G; Hausner, H; Holst, AG; Jacobsen, JB; Wagner, FD | 1 |
| Cui, X; de la Peña, A; Geiser, J; Loghin, C | 1 |
| Carroll, C; Hassanin, A | 1 |
1 review(s) available for atorvastatin and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 trial(s) available for atorvastatin and digoxin
| Article | Year |
|---|---|
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Digoxin; Dose-Response Relationship, Drug; Drug Interactions; Female; Heptanoic Acids; Humans; Intestinal Mucosa; Male; Middle Aged; Pyrroles; Time Factors; Verapamil | 2000 |
Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Topics: Adult; Amides; Animals; Antifungal Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Female; Fumarates; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketoconazole; Male; Organic Anion Transporters; Pyrroles; Renin; Tissue Distribution; Young Adult | 2008 |
Absence of clinically relevant interactions between rivaroxaban--an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects.
Topics: Adult; Anti-Arrhythmia Agents; Atorvastatin; Cross-Over Studies; Digoxin; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Headache; Heptanoic Acids; Humans; Male; Middle Aged; Morpholines; Pyrroles; Rivaroxaban; Self Administration; Thiophenes; Young Adult | 2012 |
Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Antihypertensive Agents; Atorvastatin; Biopharmaceutics; Cardiotonic Agents; Computer Simulation; Cross-Over Studies; Digoxin; Double-Blind Method; Drug Interactions; Female; Gastric Emptying; Gastrointestinal Absorption; Griseofulvin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liraglutide; Lisinopril; Male; Middle Aged; Therapeutic Equivalency; Tissue Distribution; Young Adult | 2015 |
Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.
Topics: Adult; Area Under Curve; Atorvastatin; Digoxin; Female; Healthy Volunteers; Humans; Male; Membrane Transport Proteins; Metformin; Methotrexate; Middle Aged; Nitriles; Pyridines; Triazoles; Young Adult | 2017 |
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
Topics: Adolescent; Adult; Atorvastatin; Cross-Over Studies; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Warfarin; Young Adult | 2017 |
No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Atorvastatin; Contraceptives, Oral; Digoxin; Drug Interactions; Female; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Injections, Subcutaneous; Male; Middle Aged; Recombinant Fusion Proteins; Warfarin; Young Adult | 2017 |
9 other study(ies) available for atorvastatin and digoxin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
A case of recurrent ventricular tachycardia.
Topics: Aged; Atorvastatin; Cardiovascular Agents; Digoxin; Drug Therapy, Combination; Female; Furosemide; Heptanoic Acids; Humans; Isosorbide Dinitrate; Lisinopril; Nitroglycerin; Pyrroles; Recurrence; Tachycardia, Ventricular; Warfarin | 2011 |
Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Digoxin; Heptanoic Acids; Intestinal Absorption; Pyrroles; Rats; Rats, Sprague-Dawley; Verapamil | 2013 |
Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Catechin; Cells, Cultured; Digoxin; HEK293 Cells; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Metformin; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Solute Carrier Organic Anion Transporter Family Member 1B3; Tea; Tissue Distribution | 2015 |
Polypharmacy in the Elderly-When Good Drugs Lead to Bad Outcomes: A Teachable Moment.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atorvastatin; Atrial Fibrillation; Bone Density Conservation Agents; Deprescriptions; Digoxin; Diltiazem; Diuretics; Drug Overdose; Factor Xa Inhibitors; Female; Furosemide; Heart Failure; Histamine H1 Antagonists, Non-Sedating; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Lisinopril; Loratadine; Metoprolol; Polypharmacy; Pyrazoles; Pyridones; Ranitidine; Syncope | 2017 |